Cytarabine ocfosfate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341175

CAS#: 73532-83-9

Description: Cytarabine ocfosfate is a biochemical.


Chemical Structure

img
Cytarabine ocfosfate
CAS# 73532-83-9

Theoretical Analysis

MedKoo Cat#: 341175
Name: Cytarabine ocfosfate
CAS#: 73532-83-9
Chemical Formula: C27H50N3O8P
Exact Mass: 575.3336
Molecular Weight: 575.6838
Elemental Analysis: C, 56.33; H, 8.75; N, 7.30; O, 22.23; P, 5.38

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cytarabine ocfosfate; YNK 01; YNK-01; YNK01.

IUPAC/Chemical Name: 2(1H)-Pyrimidinone, 4-amino-1-(5-O-(hydroxy(octadecyloxy)phosphinyl)-beta-D-arabinofuranosyl)-

InChi Key: YJTVZHOYBAOUTO-URBBEOKESA-N

InChi Code: InChI=1S/C27H50N3O8P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20-36-39(34,35)37-21-22-24(31)25(32)26(38-22)30-19-18-23(28)29-27(30)33/h18-19,22,24-26,31-32H,2-17,20-21H2,1H3,(H,34,35)(H2,28,29,33)/t22-,24-,25+,26-/m1/s1

SMILES Code: CCCCCCCCCCCCCCCCCCOP(=O)(O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=CC(=NC2=O)N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 575.6838 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Arahata M, Shimizu Y, Asakura H, Nakao S. Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate. J Hematol Oncol. 2015 Feb 6;8:5. doi: 10.1186/s13045-014-0100-6. PubMed PMID: 25652695; PubMed Central PMCID: PMC4332927.

2: Horikoshi A, Iriyama N, Hirabayashi Y, Kodaira H, Matsukawa Y, Uchino Y, Takahashi H, Hatta Y, Takeuchi J, Kobayashi S, Miura K. Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients. Chemotherapy. 2013;59(2):152-8. doi: 10.1159/000351114. Epub 2013 Sep 27. PubMed PMID: 24080768.

3: Horikoshi A, Takei K, Hosokawa Y, Sawada S. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. Int J Hematol. 2008 Mar;87(2):118-125. doi: 10.1007/s12185-007-0019-6. Epub 2008 Jan 30. PubMed PMID: 18228114.

4: Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E, Oshima K, Inoue M, Izutsu K, Watanabe T, Motokura T, Chiba S, Fukayama M, Kurokawa M. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol. 2007 May;82(5):386-90. PubMed PMID: 17109389.

5: Mollee P, Arthur C, Hughes T, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, Seymour JF, Martin N, Shina S, Low C, Wright S, Rodwell R, Coulston J, Morton J, Blacklock H, Taylor D, Taylor KM. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Ann Oncol. 2004 Dec;15(12):1810-5. PubMed PMID: 15550587.

6: Kalambokis G, Stefanou D, Arkoumani E, Kitsanou M, Bourantas K, V Tsianos E. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur J Haematol. 2004 Jul;73(1):67-70. PubMed PMID: 15182341.

7: Ide K, Momoi Y, Minegishi M, Sekiguchi M, Konno K, Iwasaki T. A severe hepatic disorder with myelodysplastic syndrome, treated with cytarabine ocfosfate, in a dog. Aust Vet J. 2003 Jan-Feb;81(1-2):47-9. PubMed PMID: 15084010.

8: Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet. 2002;41(10):705-18. Review. PubMed PMID: 12162758.

9: Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J, Tertain G, Blanc M, Bauduer F, Brière J, Abgrall JF, Pegourie-Bandelier B, Solary E, Cambier N, Coso D, Vilque JP, Delain M, Harousseau JL, Rousselot P, Belhadj K, Morice P, Attal J, Chabin M, Chastang C, Guilhot J, Guilhot F; France Intergroupe des Leucémies Myéloïdes Chroniques. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia. 2002 Apr;16(4):573-80. PubMed PMID: 11960335.

10: Gotoh A, Miyazawa K, Uchida Y, Sashida G, Kawakubo K, Kuriyama Y, Ohyashiki K. Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis. Int J Hematol. 2002 Feb;75(2):191-4. PubMed PMID: 11939268.

11: Seo T, Fukushima T, Inoue H, Imamura S, Urasaki Y, Yoshida A, Kawai Y, Yamauchi T, Iwasaki H, Tsutani H, Nakamura T, Ueda T. Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single institute. J Infect Chemother. 2001 Sep;7(3):156-62. PubMed PMID: 11810577.

12: del Cañizo MC, Fisac MP, Galende J, Hurtado JA, Moro MJ, Rodriguez JA, Rivas JM, Tabernero MD; Castellano-Leonés Group on CML. Continuous oral cytarabine ocfosfate with interferon-alpha-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study. Br J Haematol. 2001 Dec;115(3):541-4. PubMed PMID: 11736933.

13: Cervantes F, Sureda A, Hernández-Boluda JC, Martino R, Brunet S, Borrego D, Antich JL, Montserrat E. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon. Haematologica. 2001 Dec;86(12):1281-6. PubMed PMID: 11726320.

14: Johnson SA. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother. 2001 Jun;2(6):929-43. Review. PubMed PMID: 11585009.

15: Reiter A, Hochhaus A, Berger U, Kuhn C, Hehlmann R. AraC-based pharmacotherapy of chronic myeloid leukaemia. Expert Opin Pharmacother. 2001 Jul;2(7):1129-35. Review. PubMed PMID: 11583064.

16: Ontachi Y, Yamauchi H, Takami A, Asakura H, Nakao S. [Low dose melphalan therapy was effective in an elderly patient with MDS-AML]. Nihon Ronen Igakkai Zasshi. 2001 May;38(3):405-8. Japanese. PubMed PMID: 11431899.

17: Kühr T, Eisterer W, Apfelbeck U, Linkesch W, Bechter O, Zabernigg A, Geissler K, Barbieri G, Duba C, Gastl G, Thaler J. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study. Leuk Res. 2000 Jul;24(7):583-7. PubMed PMID: 10867132.

18: Ohnishi K. [Oral antitumor drugs for hematological malignancies]. Gan To Kagaku Ryoho. 1999 Feb;26(3):295-300. Review. Japanese. PubMed PMID: 10065091.

19: Yamada T, Tsurumi H, Hara T, Sawada M, Oyama M, Moriwaki H. [Cytarabine-induced pericarditis]. Rinsho Ketsueki. 1998 Nov;39(11):1115-20. Japanese. PubMed PMID: 9866424.

20: Suto T, Yoshida Y, Sakata Y, Ono T, Yoshida T, Yamada N, Chida N, Oohira H. [Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1998 Oct;25(12):1933-8. Japanese. PubMed PMID: 9797816.